| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 7250 |
| 1 | ENZALUTAMIDE | 4575 |
| 2 | PEMBROLIZUMAB | 4564 |
| 3 | EVEROLIMUS | 3795 |
| 4 | CARBOPLATIN | 3021 |
| 5 | DEXAMETHASONE | 2745 |
| 6 | CAPECITABINE | 2651 |
| 7 | IPILIMUMAB | 2619 |
| 8 | LETROZOLE | 2381 |
| 9 | FULVESTRANT | 2281 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AFATINIB | 1456 | 0.2695 |
| 1 | CERITINIB | 368 | 0.1909 |
| 2 | GEFITINIB | 1468 | 0.1870 |
| 3 | PRALATREXATE | 76 | 0.1652 |
| 4 | RUCAPARIB | 1009 | 0.1555 |
| 5 | OLAPARIB | 1104 | 0.1485 |
| 6 | RAMUCIRUMAB | 568 | 0.1445 |
| 7 | PEMBROLIZUMAB | 4564 | 0.1425 |
| 8 | OSIMERTINIB | 1506 | 0.1322 |
| 9 | STREPTOZOCIN | 18 | 0.1295 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 12586 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 11842 |
| 2 | Corticosteroid [EPC] | 5375 |
| 3 | Platinum-based Drug [EPC] | 5264 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 5019 |
| 5 | Androgen Receptor Inhibitor [EPC] | 4894 |
| 6 | mTOR Inhibitor Immunosuppressant [EPC] | 3842 |
| 7 | Aromatase Inhibitor [EPC] | 3753 |
| 8 | Microtubule Inhibitor [EPC] | 3682 |
| 9 | Alkylating Drug [EPC] | 2931 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 568 | 0.1445 |
| 1 | Estrogen Receptor Antagonist [EPC] | 2281 | 0.1282 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 11842 | 0.1160 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 533 | 0.1066 |
| 4 | CTLA-4-directed Blocking Antibody [EPC] | 2619 | 0.0986 |
| 5 | Androgen Receptor Inhibitor [EPC] | 4894 | 0.0852 |
| 6 | Radioactive Therapeutic Agent [EPC] | 10 | 0.0847 |
| 7 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 1519 | 0.0819 |
| 8 | Catecholamine Synthesis Inhibitor [EPC] | 2 | 0.0625 |
| 9 | SLAMF7-directed Immunostimulatory Antibody [EPC] | 202 | 0.0529 |